Neurology | Phase I Developments | Pipeline Prospector

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

Lead Product(s): PF-05251749

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Biogen

Deal Size: $710.0 million Upfront Cash: $75.0 million

Deal Type: Acquisition January 13, 2020

Details:

With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.

AC Immune

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Lead Product(s): ACI-3024

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: $105.1 million Upfront Cash: Undisclosed

Deal Type: Collaboration March 23, 2020

Details:

The collaboration combines AC Immune’s proprietary Morphomer discovery platform technology and early development experience with Lilly’s clinical development expertise and commercial capabilities.

Kuur Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies

Lead Product(s): CMD-501

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: IP Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 10, 2020

Details:

The funding two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT cells in CD19 malignancy).

Sorrento Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

Lead Product(s): Resiniferatoxin

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

Safety in the higher dose cohort is expected to be supportive for testing RTX epidural administration in other advanced non-cancer disease related unmet clinical needs.

uniQure

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference

Lead Product(s): rAAV5-miHTT

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

Up to two years of follow-up in large transgenic huntington’s disease model demonstrates stable mHTT protein lowering.

RegeneRx Bioprmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy

Lead Product(s): Thymosin Beta-4

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

RegeneRx in-licensed the intellectual property relating to the use of T?4 from the Henry Ford Hospital System in Detroit, MI based on work performed by Dr. Michael Chopp and his colleagues.

Alector

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Alector Announces FDA Fast Track Designation Granted to AL101

Lead Product(s): AL101

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2020

Details:

AL101, the company’s second product candidate designed to restore progranulin levels in the brain, is currently being evaluated in a Phase 1 trial in healthy volunteers.

Alkahest

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in PD

Lead Product(s): AKST4290

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

The trial, AKST4290-211, is funded in part by The Michael J. Fox Foundation for Parkinson’s Research and will evaluate the effect of AKST4290 on motor function in Parkinson’s disease.

Vertex Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Vertex drops VX-961 to continue search for perfect pain drug

Lead Product(s): VX-961

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

The NaV1.8 inhibitor did not meet the desired pharmacokinetic and tolerability profile which led to the dumping of the drug and detail plans to move a follow-up product to the clinic.

Orexo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain

Lead Product(s): Ketorolac

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

OX338 demonstrated improved bioavailability and tolerability compared to commercially available reference product.

Find

Find Neurology Drugs in Phase I Clinical Development

Phase I

A collaboration with SCORR Marketing

Product Type

Companies

Pfizer Inc

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

AC Immune

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Kuur Therapeutics

Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies

Sorrento Therapeutics

Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

uniQure

uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference

RegeneRx Bioprmaceuticals

RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy

Alector

Alector Announces FDA Fast Track Designation Granted to AL101

Alkahest

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in PD

Vertex Pharmaceuticals

Vertex drops VX-961 to continue search for perfect pain drug

Orexo

Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain